학술논문

Clinical Practice Guideline for Headache Disorders 2021 : A new compass for navigating headache management / 頭痛の診療ガイドライン2021:片頭痛診療の新しい羅針盤
Document Type
Journal Article
Source
神経治療学 / Neurological Therapeutics. 2023, 40(4):542
Subject
Clinical Practice Guideline for Headache Disorders 2021
ICHD–3
calcitonin gene–related peptide (CGRP)
migraine
neuromodulation
Language
Japanese
ISSN
0916-8443
2189-7824
Abstract
Clinical Practice Guideline for Headache Disorders 2021 was published in 2021, in which the GRADE system was adopted in the section of acute migraine therapy. The number of clinical questions was increased to 132. There have been a number of notable changes in headache medicine. The International Headache Society released the International Headache Classification of Headache Disorders, 3rd Edition (ICHD–3) in 2018, which made some important modifications in classification and diagnostic criteria of headache disorders. Moreover, basic and clinical research has advanced our understanding on the pathophysiology of headache disorders. As a consequence, calcitonin gene–related peptide (CGRP)–targeted therapy was introduced to the treatment of migraine and cluster headache. In particular, this novel therapy has had a great impact on migraine prevention. Furthermore, novel therapeutic approaches, such as non–invasive neuromodulation and cognitive and behavioral therapy, are in clinical use. The new clinical guideline provides clinically relevant information on headache management, thus serving as a new compass for navigating headache management in the new era.